COMMENTARY

Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries

Martina Penazzato1, Linda Lewis2, Melynda Watkins2, Vineet Prabhu2, Fernando Pascual3, Martin Auton4, Wesley Kreft5, Sébastien Morin6, Marissa Vicari6, Janice Lee7, David Jamieson8 and George K Siberry9

§Corresponding author: Martina Penazzato, World Health Organization, Avenue Appia 20, 1202 Genève, Switzerland. Tel: +41 79 446 6493. (penazzatom@who.int)

All authors have contributed equally.

Abstract

Introduction: Despite the coordinated efforts by several stakeholders to speed up access to HIV treatment for children, development of optimal paediatric formulations still lags 8 to 10 years behind that of adults, due mainly to lack of market incentives and technical complexities in manufacturing. The small and fragmented paediatric market also hinders launch and uptake of new formulations. Moreover, the problems affecting HIV similarly affect other disease areas where development and introduction of optimal paediatric formulations is even slower. Therefore, accelerating processes for developing and commercializing optimal paediatric drug formulations for HIV and other disease areas is urgently needed.

Discussion: The Global Accelerator for Paediatric Formulations (GAP-f) is an innovative collaborative model that will accelerate availability of optimized treatment options for infectious diseases, such as HIV, tuberculosis and viral hepatitis, affecting children in low- and middle-income countries (LMICs). It builds on the HIV experience and existing efforts in paediatric drug development, formalizing collaboration between normative bodies, research networks, regulatory agencies, industry, supply and procurement organizations and funding bodies. Upstream, the GAP-f will coordinate technical support to companies to design and study optimal paediatric formulations, harmonize efforts with regulators and incentivize manufacturers to conduct formulation development. Downstream, the GAP-f will reinforce coordinated procurement and communication with suppliers. The GAP-f will be implemented in a three-stage process: (1) development of a strategic framework and promotion of key regulatory efficiencies; (2) testing of feasibility and results, building on the work of existing platforms such as the Paediatric HIV Treatment Initiative (PHTI) including innovative approaches to incentivize generic development and (3) launch as a fully functioning structure.

Conclusions: GAP-f is a key partnership example enhancing North-South and international cooperation on and access to science and technology and capacity building, responding to Sustainable Development Goal (SDG) 17.6 (technology) and 17.9 (capacity-building). By promoting access to the most needed paediatric formulations for HIV and high-burden infectious diseases in low-and middle-income countries, GAP-f will support achievement of SDG 3.2 (infant mortality), 3.3 (end of AIDS and combat other communicable diseases) and 3.8 (access to essential medicines), and be an essential component of meeting the global Start Free, Stay Free, AIDS Free super-fast-track targets.

Keywords: paediatric drugs; drug development; drug formulations; regulatory approval; Global Accelerator for Paediatric Formulations; HIV; tuberculosis; viral hepatitis

Received 22 May 2017; Accepted 18 December 2017; Published 27 February 2018

Copyright © 2018 World Health Organization; licensee IAS. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article, there should not be any suggestion that WHO or this article endorse any specific organisation or products. The use of the WHO logo is not permitted.

1 | INTRODUCTION

Prompt treatment of people living with HIV (PLHIV) with appropriate antiretroviral drugs (ARVs) saves lives and improves health, but the 43% ARV treatment (ART) coverage of children living with HIV (CLHIV, <15 years old) continues to lag behind adult coverage [1], and many CLHIV in low- and middle-income countries (LMIC) still do not receive optimal paediatric formulations. In an era that has seen the major public health achievement of 18.2 million people accessing ARVs worldwide in 2016 [1] and new fast track targets to end AIDS by 2030 [2], drug development for children surprisingly still lags 8 to 10 years behind that of adults [3]. There are many demographic, structural, regulatory, technical and economic challenges slowing drug development for children. The 2.1 million CLHIV globally make up less than 10% of all PLHIV, but require combinations, strengths and formulations of ARVs that vary by age and weight. The result is a
DISCUSSION

2.1 What is GAP-f?

Since 2013, under the coordination of the World Health Organization (WHO), cross-sectoral collaboration in paediatric HIV has increased among key stakeholders addressing medium- and long-term prioritization of most needed paediatric formulations for development. This has been accomplished through several ongoing initiatives:

1. The Paediatric ARV Drug Optimization (PADO) group sets priorities for development of new ARV drug formulation for children.
2. The Paediatric ARV Working Group (PAWG) provides technical guidance on weight-band dosing and pharmacokinetic and acceptability studies of ARV drugs in children.
3. The Interagency Task Team on Prevention of HIV Transmission in Pregnant Women, Mothers and their Children (IATT) develops a Paediatric ARV Formulary of existing drug formulations needed from manufacturers to enable optimal treatment of children.
4. The Paediatric ARV Procurement Working Group (PAPWG) coordinates procurement of paediatric ARVs for approximately 70 LMIC programmes.

In 2014, UNITAID, the Drugs for Neglected Diseases initiative (DNDI) and the Medicines Patent Pool (MPP), launched the Paediatric HIV Treatment Initiative (PHTI), to develop and deliver specific paediatric formulations; the Clinton Health Access Initiative (CHAI) joined the PHTI later. Later in 2014, partners came together to advance the paediatric HIV agenda under the umbrella of the Global Pediatric Antiretroviral Commitment-to-Action (CTA). Several broad consultations held in 2016 [7-9] explored mechanisms to advance paediatric formulation development and introduction. In parallel, two meetings organized under the leadership of the Holy See [10] generated high-level support to facilitate closer collaboration between the private sector and relevant stakeholders. These efforts to support paediatric formulation development and uptake are essential elements of the AIDS Free agenda of the Start Free, Stay Free, AIDS Free super-fast-track framework for ending AIDS in children, adolescents and young women by 2020, launched by UNAIDS and PEPFAR in 2016 [11].

The GAP-f brings together these efforts through establishment of a more formalized mechanism with collaboration upstream (clinical and formulation development by innovators and generics; stringent drug regulatory authority filing and approval processes; optimized paediatric product testing and generic manufacturing) and downstream (country-level drug regulatory approval; national treatment policy; supply chain management; programme sensitization; market uptake and incentives). The GAP-f will streamline efforts currently underway, integrating and consolidating all stakeholders invested in different steps of the pathway of paediatric drug prioritization, development, manufacture and uptake into a coherent, single-framework mechanism (see Figure 1).

2.2 Finding efficiencies upstream

Currently, the development of paediatric products is closely dependent on development of products for adults, although it
presents additional challenges (see Figure 2). Efficacy of most
drugs (including ARVs) in children is extrapolated from results
of clinical trials conducted in adults; direct studies of safety
and dosing in children across the paediatric age and weight
spectrum are then required. Through the submission of
paediatric investigation plans [PIP, at the European Medicines
Agency (EMA)] or paediatric study plans [PSP, at the United
States Food and Drug Administration (US FDA)], innovator
companies commit to generate supportive data in children
required for authorization of a medicine for paediatric use.
These plans, compulsory for all companies seeking marketing
approval unless they obtain a waiver or a deferral, are submit-
ted very early in drug development, and include non-clinical
and clinical study plans [12,13]. The execution of these plans
starts after proof of concept of the adult product and repre-
sents a large investment from pharmaceutical companies.

Formulation development is also a critical element of
paediatric drug development. Paediatric products must be
age-appropriate formulations for the intended age groups,
apalatable and easy to administer in appropriate doses. In the
past, most paediatric formulations were oral liquids, which are
difficult to store, may need refrigeration, entail more complex
administration (with higher risk of dosing errors) and are more
difficult for making fixed-dose combination (FDC) products.
However, WHO currently recommends dispersible tablets,
granules or other solid formulations (that do not require
whole pill swallowing), preferably in FDCs, to avoid the com-
plexities linked to liquid administration [14]. Currently, there
are several key regimens recommended by WHO available in
such child-friendly formulations (e.g. ABC/3TC dispersible
tables, LPV/r pellets), but still more are needed. In addition, it
is important to ensure that future products are developed fol-
lowing these recommendations.

Because the paediatric market for HIV and other infectious
disease products is small, innovator companies that have pre-
viously developed and launched paediatric formulations imper-
fectly adapted for use in LMICs are unlikely to reformulate
their products. In such cases, generic companies may be best
placed to manufacture alternate formulations for existing
products when patents expire or when the innovator compa-
nies grant voluntary licences (VL) permitting generic versions
of drugs with remaining patent protection. Since 2010, the
MPP has been striving to negotiate VL agreements with inno-
vatators of HIV, hepatitis C and tuberculosis medicines [15].
To date, all innovators have granted VLs to the MPP for all
WHO-recommended paediatric ARVs still under patent (ex-
cept for darunavir, for which Janssen announced intent not to
enforce patents in resource-limited settings [16]).

Regulatory approval of novel formulations, especially new
FDC products for which component drugs are owned by dif-
ferent innovators, was previously out of the scope of stringent
regulatory authorities (SRA). In the last decade, several initia-
tives have addressed some of these limitations mainly in the
field of HIV. In 2006, as part of the President’s Emergency
Plan for AIDS Relief (PEPFAR), the US FDA identified a mech-
anism to grant tentative approval to ARV products intended
for procurement in developing countries while maintaining
patent protection within the US [17]. EMA now gives to man-
ufacturers, scientific opinion on the regulatory requirements
for products intended for non-EU markets through the Article
58 procedure. In addition, the WHO prequalification team
assesses products and inspects manufacturing plants. As a
result, several paediatric-adapted formulations, including sev-
eral dispersible FDCs for HIV, TB and malaria, that meet the
high SRA standards for efficacy, safety and quality are avail-
able to children in LMICs.

A good illustration of the paediatric development process is
the FDC containing abacavir (ABC) and lamivudine (3TC), key
components of WHO-recommended first-line HIV treatment
for children (see Figure 3). The innovator conducted clinical
trials in the 1990s to establish the appropriate dose for chil-
dren. The US FDA approved the oral solutions in 1995 (3TC)
and 1998 (ABC). The first generic dispersible tablet containing
a combination of the two products was approved in 2011 and
was only available in countries where there was no patent
restriction. Only in 2014, four years after WHO
Figure 2. The GAP-f represents an opportunity to address challenges in pediatric drug formulation development. Challenges are grouped around three areas: dependence on adult drug development, pediatric formulation requirements and pediatric ARV market. Progress to-date in addressing these challenges is depicted along a funnel originating from precursor mechanisms and leading up to the GAP-f collaborative model. Legal framework challenges are placed outside of the funnel because of the limited influence of the GAP-f to directly address these. PK, pharmacokinetic; GAP-f, Global Accelerator for Pediatric Formulations; ARV, antiretroviral.

Figure 3. Timeline for ABC/3TC development. It took almost 15 years after ABC and 3TC were first approved for use in children until enough generic versions of child-friendly formulations were produced to make these drugs widely available to children in LMIC. ABC, abacavir; 3TC, lamivudine; LMIC, low- and middle-income countries.
The paediatric ARV market, despite growth over the last 10 years, remains relatively small and fragile. To address procurement and access challenges, the PAPWG was created to lead global collaboration and coordination among key partners, including procurement that promotes optimal products. This effort has succeeded in consolidating the number of different paediatric ARV products procured and increasing the share of paediatric products procured that correspond to WHO-preferred products for children. Following success in the paediatric market, in 2016, the group expanded its scope to include low-volume adult ARV products, and was renamed the ARV Procurement Working Group (APWG).

The theory of change underpinning the APWG is that coordinated procurement, where orders are consolidated with predictable ordering schedules, reduces lead times and avoids stock-outs. Coordination occurs at the global level between member procurers, who in turn coordinate with their client programmes to negotiate acceptability of any adjustments. Sharing market intelligence across large funders and buyers ensures both visibility and confidence for manufacturers and supplier accountability. Supply disruptions are minimized and ARV markets are shepherded towards optimal formulations that benefit patients the most. The APWG consists of major funders and buyers like the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR, UNICEF, national procurement units from Kenya and Ethiopia, and partners like UNITAID and CHAI. (It does not currently include South Africa procurement units.) Its approach includes:

1. Consolidated ordering at set times each quarter to ensure any one product has sufficient orders to fulfil a supplier’s minimum batch size (ranging from 5000 to 50,000 packs). A quarterly review of planned procurements identifies potential issues around sub-batch size and extended lead times are flagged early for corrective action. Buying plans can be adjusted while allowing members to adhere to their respective organizational policies.

2. Optimizing product selection using the formulary list developed by the IATT [19], and WHO guidelines on ART [14].

3. Aggregating a rolling quarterly forecast across procurers of demand by delivery quarter for the next 12 to 18 months to help suppliers with market visibility and production planning.

4. Regular structured dialogue between buyers, programmes and manufacturers to ensure timeliness and consistency of information sharing.

5. Collaboration with procurement partners to support improvement of country paediatric forecasting, procurement practices and supply management.

The APWG, responsible for well over half the global demand, has made great strides in stabilizing and streamlining the paediatric ARV market by consolidating volumes: lead times have reduced sharply, there is less fragmentation in product selection, and in 2016 less than 5% of orders by volume were “non-essential” formulations as defined by the IATT. The APWG is an important body for downstream efforts to ensure that the new paediatric products are not only developed, but also realize their full potential in improving the lives of CLHIV, consistent with the targets of SDG 3.

2.4 | Implementing the GAP-f

The GAP-f will ensure coordination among partners working in different areas in the paediatric field to achieve faster development and uptake of the most needed drugs for children. Implementation of the GAP-f is conceptualized as a 3-stage process:
1 Stage: Strategic development, consensus on activities to accelerate paediatric drug optimization and formalization of partner and stakeholder engagement.

2 Stage: Testing acceleration model for feasibility and results.

3 Stage: Launch of the GAP-f as a fully functioning, sustainable structure informed by the evaluations of Stages 1 and 2.

The first stage will promote more visibility on the future market of individual priority products and regulatory efficiencies through increased coordination of the PIP/PSP processes in the European Union (EU) and the US:

1 Development of a harmonized master protocol for paediatric clinical, bioequivalence and palatability studies;

2 Increased engagement in high-burden countries towards prioritizing registration of PADO priority products for children; and

3 Strategic assessment of timelines and durability of priority products (as prioritized by PADO).

In Stage 2, GAP-f will build on the work of the PHTI to test its model for feasibility and results. This will include facilitation of early, effective engagement between innovators and paediatric HIV clinical trials networks to collaborate on the design of initial paediatric studies. Innovative approaches to incentivize generic development of priority products and promotion of earlier collaboration between innovators and generic manufacturers so that the generics can potentially be part of innovators’ development team and perform early child-friendly formulation development will be considered. In collaboration with country partners, GAP-f will develop harmonized messaging to ensure future market demand for priority products, simplified guidance for product introduction and product scale-up plans.

In its full genesis as an independent entity (Stage 3), the GAP-f will sustain and support activities and interventions proven to be effective in its initial stages. The experiences and lessons learned will inform the design of a fully functioning structure, which will coordinate and facilitate upstream and downstream activities detailed above. Evaluation of the impact of Stage 1 coordination efforts and promotion of more efficient drug trial designs in children and of Stage 2 examples of innovative financing and facilitated innovator-generic manufacturer collaboration in paediatric formulation development will be incorporated into the final design of Stage 3 of GAP-f. The GAP-f mechanism will build on the HIV experience and subsequently expand its scope to include paediatric formulations of drugs for other critical disease areas, such as tuberculosis and viral hepatitis, which present a number of similar challenges.

3 | CONCLUSIONS

The experience gained in paediatric HIV showed that the current separate work streams for development and uptake of paediatric formulations fall short to deliver optimal formulations for children and that a more structured and efficient collaboration is required. The GAP-f proposes an innovative collaborative model, endorsed by key stakeholders, which will allow accelerated availability of safe, effective, quality-assured and affordable paediatric medicines. It is essential to achieve the Start Free, Stay Free, AIDS Free super-fast-track targets of ending AIDS in children and adolescents by 2020 and will contribute to SDG 3 of reducing child mortality, ending AIDS and tuberculosis, and combating hepatitis. In addition, the GAP-f represents an example of international access to innovation and effective public-private partnerships, thus contributing also to SDG 17. The GAP-f represents an example of extensive collaboration built on existing initiatives and partners’ expertise, with an ambitious overarching goal of accelerating access to best treatment options for diseases affecting children primarily in LMICs, such as HIV, tuberculosis, viral hepatitis and other infectious (and non-communicable) diseases subject to similar market failures.

AUTHORS’ AFFILIATIONS

1 World Health Organization, Geneva, Switzerland; 2 Clinton Health Access Initiative, Boston, MA, USA; 3 Medicines Patent Pool, Geneva, Switzerland; 4 The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland; 5 Partnership for Supply Chain Management, Amsterdam, the Netherlands; 6 International AIDS Society, Geneva, Switzerland; 7 Drugs for Neglected Diseases Initiative, Geneva, Switzerland; 8 Partnership for Supply Chain Management, Washington, DC, USA; 9 Office of the U.S. Global AIDS Coordinator, U.S. Department of State, Washington, DC, USA

COMPETING INTERESTS

MP, LL, MW, VP, FP, MA, WK, SM, MV, JL, DJ and GS have no competing interests to declare.

AUTHORS’ CONTRIBUTIONS

All authors contributed equally to drafting the content, editing and reviewing the manuscript for final endorsement.

ACKNOWLEDGEMENTS

The authors thank all stakeholders who have contributed to the development of the GAP-f concept.

FUNDING

Part of this work (SM, MV) was supported by the International AIDS Society’s Collaborative Initiative for Paediatric HIV Education and Research which is made possible through funding from founding sponsor ViiV Healthcare and from Janssen, and Industry Liaison Forum, through contributions from its 2016 and 2017 Gold Partners (Gilead Sciences, MSD and ViV Healthcare), Silver Partners (AbbVie, Alere and Janssen) and Bronze Partners (Abbott, Beckman Coulter, bioLytical Laboratories, Cepheid, Cipla, Female Health Company, Lupin Pharmaceuticals, Omega Diagnostics, Roche Molecular Systems and Sysmex Corporation). Technical expertise for this document was supported in part (GS) by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

DISCLAIMER

This manuscript represents the views of the authors, and the findings and conclusions included here do not necessarily represent the views of the World Health Organization or the United States government.

REFERENCES

1. UNAIDS. UNAIDS Data 2017 [Internet]. Available from: http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf
2. Fast-Track: ending the AIDS epidemic by 2030 [Internet]. Available from: http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
3. Burger DM, Van Russum AM. Improved labelling of antiretrovirals for paediatric use. Lancet. 2016;3(12):e550–1.

83
4. Lee JSF, Sagaon Teyssier L, Dongmo Nquimfak B, Collins IJ, Lallemant M, Perriens J, et al. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012. BMC Pediatr. 2016;15(16):41.

5. Penazzato M, Gnanashanmugam D, Rojo P, Lallemant M, Lewis L, Rocchi F, et al. Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations. Clin Infect Dis. 2017;64(11):1597–603.

6. Start FREE, Stay Free, AIDS Free [Internet]. Available from: https://free.unaids.org

7. CTA/ILF/CIPHER. Thematic roundtable on paediatric ARVs: fast tracking development of priority formulations, July 2016 [Internet]. Available from: http://bit.ly/2f9QXii

8. ILF/CIPHER thematic roundtable on paediatric ARVs: stimulating development of the most needed formulations. March 2016 [Internet]. Available from: http://bit.ly/1S31ZML

9. CTA meeting on paediatric ARVs: introducing the Global Accelerator for Paediatric Formulations, December 2016 [Internet]. Available from: http://www.iasociety.org/HIV-Programmes/Programmes/Industry-Liaison-Forum/Events/CTA-Meeting-on-Paediatric-ARVs

10. Second meeting of the directors of pharmaceutical and diagnostic industries for children living with HIV (16-17 May 2016).

11. A super-fast-track framework for ending aids in children, adolescents and young women by 2020 [Internet]. [cited 2017 May 15]. Available from: https://free.unaids.org

12. Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use. 2006.

13. US Food and Drug Administration, Guidance for Industry: Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry. 2016.

14. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach second edition. Geneva: 2016.

15. The MPP Annual Report 2015: Five Years of Patent Pooling for Public Health. 2015.

16. Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings. 2012.

17. US Food and Drug Administration. Guidance for Industry: Fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV. 2006.

18. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision. Geneva; 2010.

19. IATT Paediatric ARV formulary and limited-use list: 2016 update [Internet]. Geneva; 2016. Available from: http://apps.who.int/medicinedocs/documents/s23120en/s23120en.pdf